Introduction: Nephrotic syndrome (NS) is a characterized by massive proteinuria, edema, hypoalbuminemia, and dyslipidemia. Glucocorticoids (GCs), the primary therapy for >60 years, are ineffective in approximately 50% of adults and approximately 20% of children. Unfortunately, there are no validated biomarkers able to predict steroid-resistant NS (SRNS) or to define the pathways regulating SRNS.
patients being labeled as having SRNS. Unfortunately, no validated biomarkers have yet been identified that are able to predict steroid resistance, leaving patients at high risk for both toxic side effects of GC treatment, as well as disease progression. Thus, the identification and validation of biomarkers able to predict the clinical response to GC before the initiation of treatment could enable avoidance of GC-induced drug toxicity, and rapid initiation of alternative treatments more likely to induce remission and delay or prevent disease progression. In addition, the identification of candidate biomarkers able to determine specific molecular pathways and targets associated with clinical steroid resistance could enable the development of more effective and less toxic targeted future therapies for NS.
Mass spectrometric-based discovery proteomic methods have contributed significantly to our understanding of idiopathic renal disease by identification of proteins integral to disease processes. 3, 4 State-of-the-art methods have the ability to characterize both high-and low-abundant proteins and develop both qualitative data to identify proteins and to suggest relative abundance or absolute concentration differences. [5] [6] [7] [8] These studies and other "omics" studies are providing valuable pilot and confirmatory information for the identification of disease biomarkers. [9] [10] [11] [12] [13] [14] [15] Recently, a few studies have approached urinary biomarker identification using proteomics in patients with NS either classified by histology or by clinical response. 16, 17 The present studies were designed to test the primary hypothesis that proteomic analyses with subsequent validation of paired plasma samples from children with SSNS and SRNS can be used to identify biomarkers predictive of steroid resistance at the time of disease presentation before therapy (Figure 1a ). The secondary aim of the present study was to identify mechanistic molecular pathways or targets associated with clinical steroid resistance in NS (Figure 1b ). To test this hypothesis, we analyzed paired plasma biosamples collected from 2008 to 2014 through the Midwest Pediatric Nephrology Consortium from children with NS that were obtained both at the time of disease presentation (before initiation of steroid therapy) and an average of approximately 7 weeks post-GC treatment, when the clinical determination of SRNS versus SSNS was made by the treating nephrologist.
METHODS

Study Approval, Ethics Statement, Patients, and Plasma Collections
All research protocols and consent documents were approved by the institutional review board of Nationwide Children's Hospital as the coordinating center (approval numbers IRB07-00400, IRB12-00039, and IRB05-00544), as well as by each of the other participating centers of the Midwest Pediatric Nephrology Consortium. Paired plasma samples were collected for each patient, with the first sample "pretreatment" at the time of disease presentation before even a single dose of GC, and the second sample "posttreatment" after 6 to 10 weeks of GC therapy when the clinical determination of SSNS versus SRNS had been determined by the treating nephrologist. See Table 1 for patient demographics and Supplementary Methods for clinical data and sample collection details.
Proteomics Discovery Workflow
The proteomics workflow (Supplementary Figure S1 ) addressed the label-free comparison of high mass accuracy data sets developed from 15 paired patient plasma samples (n ¼ 30) using a fast protein liquid chromatography antibody-based method to immune-deplete the 20 most common plasma proteins before trypsinization. To address the limitation of small sample numbers and potential gender variability, the discovery proteomics dataset was developed with only female patient plasma samples, whereas the confirmation cohort was expanded to include both male and female patients. These data were then filtered to identify predictive and mechanistic biomarkers ( Figure 1 ) and used for various other analyses described in Supplementary Table S1 . The data filtering approaches were directed by absolute or relative differences in the protein abundance, unbiased statistical or pathways approaches, and, last, expert review of the proteomic data. These procedures of "Immuno-Depletion of Highly Abundant Proteins from Plasma, Sample Proteolysis and Liquid Chromatography-Mass Spectrometry Figure 1 . Study hypothesis and design. The present studies were designed to test the hypothesis that proteomic analyses with subsequent validation in paired plasma samples from children with steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) can be used to identify biomarkers able to (a) predict clinical steroid resistance, and (b) mechanistically define specific molecular pathways or targets associated with clinical steroid resistance.
(LCMS) Data Acquisition" are detailed in the Supplementary Material.
Informatics Analysis of LCMS Datasets
Proteome Discoverer (Thermo Fisher Scientific, Waltham, MA) v2.0.0.802 was used to analyze the data collected by the mass spectrometer with SequestHT searches performed using the July 7, 2015 version of the UniprotKB. See Supplementary Methods for details.
Immunoblot Analyses for Differential Protein Abundance
Plasma proteins were resolved on 6% to 20% gradient gels by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and immunoblotted as described in detail in the Supplementary Material. X-ray films were scanned using a calibrated ArtixScan M1 transillumination scanner (Microtek Lab, Cerritos, CA) controlled by the ScanWizard Pro program (version 7.042, Microtek International Inc., Hsinchu, Taiwan; Microtek Lab Inc., Carson, CA) using standard settings. Densitometry analyses of the integrated band densities were performed using ImageJ (version 1.39, National Institutes of Health, Bethesda, MD, standard settings; http://rsb. info.nih.gov/ij/) and values plotted using GraphPad (LaJolla, CA) Prism software version 6.00 for Windows.
Statistical Evaluation of Trends in Protein Abundance
Discovery Proteomic Studies
To determine trends in protein abundance, all censored or missing values were replaced by a minimal global protein abundance value divided by the square root of 2 (minimal observed label-free signal O O2) or 2280.3. 18 The estimations for significance of the between-group protein abundance differences were calculated using medians of protein abundance and the Mann-Whitney 1-way analysis of variance. Protein name, gene name, accession numbers, and associated protein abundance values estimated as intensity-based absolute quantification values were exported into an Excel file from Scaffold. 19 See Supplementary Methods for details.
Targeted Validation Studies
Statistical significance was determined by unpaired or paired t tests using the GraphPad Prism software version 6.00 for Windows. P values were considered significant at P < 0.05. Data shown include representative blots as well as quantitation of all the samples tested, and are displayed as means AE SEM. The ability of the quantified immunoblot data and patient sex to classify patient samples as SSNS and SRNS was determined using backward stepwise logistic regression analysis with À2log likelihood, Cox & Snell R 2 , and Nagelkerke R 2 to assess goodness of fit for the reduced terms. The sensitivity and specificity for the reduced terms to classify patient samples was determined by the area under the curve from a receiver operator characteristic. Multivariate statistical tests were performed using SAS version 9.4 (SAS Inc., Cary, NC) and SPSS version 24 (IBM Corp., Armonk, NY).
Cluster Analysis With Heatmaps
To evaluate and illustrate group trends in protein relative abundance, the intensity-based absolute quantification data were analyzed by cluster analysis with heatmap illustration. To address the dynamic range differences across the proteomic data set, the protein intensity-based absolute quantification scores were normalized on a per protein level by conversion to a mean abundance fractional value across patient samples and rescaled to absolute values of 0 to 1 per row. These normalized, fractional abundance values were used for hierarchical clustering and heatmap generation using MatLab (2016b) (MathWorks, Natick, MA) and the function "clustergram."
Pathways Analyses
The proteomic data (differentially regulated gene products with the Log2 fold change of SRNS to SSNS for both the pretreatment sample set and the posttreatment sample sets) were qualitatively assessed to provide approaches to functional annotation of data by submitting lists of identified proteins and expression patterns for pathways analysis using Ingenuity Pathways Analysis software (http://ingenuity.com). See Supplementary Methods.
RESULTS
Patients and Demographics
Eighty-eight pediatric patients were enrolled over a 10-year period, although only approximately 50% of these patients (n ¼ 45) were able to be enrolled before they received even a single dose of steroids. Of these, 37 patients with paired samples verified to include pretreatment samples and detailed clinical data were included in this study ( Table 1 ). Twenty-four of these were clinically phenotyped as SSNS, because they achieved complete remission of proteinuria within an average of approximately 7 weeks of steroid therapy, whereas 13 patients did not achieve remission and were thus phenotyped as SRNS. Approximately equal numbers of children with SSNS (n ¼ 7) and SRNS (n ¼ 8) were used for the proteomics discovery studies, and only female patients were analyzed to compensate for potential gender variability. The validation cohort was expanded to include all available male and female patients. Children with SSNS were found to be different from those with SRNS in age, height, and weight, with SRNS patients presenting at a later age than those with SSNS (9.5 vs. 5.6 years; P ¼ 0.006), consistent with known mean ages of presentation for these different forms of NS. To account for differences in pharmacodynamics of steroids in children with SSNS versus SRNS due to differences in weight, height, and body mass index, we calculated the average prescribed steroid dosage in the discovery cohort of these 2 groups. The differences in steroid dosage (SSNS, 
Pathway Mapping and Interaction Networking of Candidate Biomarkers
Ingenuity Pathway Analysis of predictive proteins (see Table 2 ) suggested 10 canonical pathways (P < 0.01) and 1 significant protein-protein network (Figure 2c and d). The top 6 canonical pathways were as follows: (i) Farnesoid X receptor/retinoid X receptor activation, (ii) liver X receptor/retinoid X receptor activation, (iii) airway pathology in chronic obstructive pulmonary disease, (iv) acute-phase response signaling, (v) hepatic fibrosis/hepatic stellate cell activation, and (vi) extrinsic prothrombin activation pathway. The principal network for the predictive biomarkers was built using 8 of 13 submitted proteins, including ADIPOQ, APOE, EFEMP1, HPX, IGFBP2, MMP-2, antithrombin-III (SERPINC1), and SHBG. As shown in Figure 2d , 5 proteins (SHBG, EFEMP1, HPX, IGFBP2, and antithrombin-III [SERPINC1]) were positioned at network edges, whereas MMP-2, ADIPOQ, APOE, and VEGF-A were positioned as network nodes, with MMP-2 and APOE nodes under the indirect regulation (dashed lines) of the cytokine tumor necrosis factor. The top 5 canonical pathways identified by Ingenuity Pathway Analysis of defining/mechanistic candidate marker gene names were (i) liver X receptor/retinoid X receptor activation, (ii) Farnesoid X receptor/retinoid X receptor activation, (iii) acute-phase response signaling, (iv) coagulation system, and (v) atherosclerosis signaling. The top 3 networks assembled by Ingenuity Pathway Analysis overlapped and had common disease/ functional attributions that included metabolic disease, hematological system development and function, inflammatory response, cell death, and survival. Network 1, but not networks 2 and 3, contained candidate biomarkers as nodal components (Supplementary Figure S5 ; MMP-2, IGFBP3, ADIPOQ, and F2). 
Biomarker Validation
Thirty-seven patients (n ¼ 74 samples) comprising 24 SSNS and 13 SRNS patients were analyzed by immunoblotting with specific antibodies for the validation of several of the predictive and mechanistic candidate biomarkers discovered previously in the proteomics analyses ( Figure 3 ). Albumin levels were analyzed as a reference protein and, as expected, it confirmed a significant difference between SSNS and SRNS posttreatment samples (Figure 3a and b) . HPX was significantly increased in the SSNS post-treatment group, but not in the SRNS group (Figure 3a and b) , thus corroborating the proteomic results (Table 3 and Figure 2 ). APOL1 was increased in both the SSNS and SRNS groups post-treatment, while maintaining the differences in its levels both pre-and post-treatment between the 2 groups (Figure 3a and b) . Although it corroborated some of the proteomics results (significant increase in SSNS and moderate increase in SRNS, Table 3 ), its confirmation also underscored its relevance as a predictive biomarker, as well as a biomarker of disease remission (difference between SSNS and SRNS both pre-and post-treatment, Figure 3 ). VDB was a very strong predictive marker of steroid resistance on validation, and it followed the same pattern between pre-and post-treatment as observed in the proteomics results (Table 3 , Figure 2 , and Figure 3a and b) . SHBG, apolipoprotein A1 (APOA1), and ADIPOQ did not show differences in pretreatment between SSNS and SRNS, although both SHBG and ADIPOQ levels were altered differently in SSNS and SRNS. MMP-2 showed 2 bands, representing the active (lower band, 64 kDa) and proenzyme (upper band, 72 kDa) forms. The relative active form of MMP-2 was significantly increased in SSNS post-treatment, and thus appears to be a potential marker to differentiate steroid sensitivity from resistance (Figure 3a-c) . The immunoblot data for the variables sex (male/ female), SHBG, VDB, HPX, APOAI, ApoL1, albumin, ADIPOQm and MMP2 were analyzed by logistic regression using a backward stepwise regression. The minimal features set remaining in the SSNS/SRNS classification model included ADIPOQ, VDB, and MMP2, but not sex. The ability of the immunoblot densitometry data for these 3 plasma proteins to classify patient samples was significant (P ¼ 0.003), with a net improvement by -2log likelihood ¼ 51.591 (Cox & Snell R 2 value ¼ 0.247; Nagelkerke R 2 value ¼ 0.332). Last, to evaluate the sensitivity and specificity for these proteins identified by logistic regression, a receiver operator characteristic curve was constructed ( Figure 4 ) and the area under the curve was calculated to be 0.78.
Proteomic Landscape With Different Approaches
Additional analyses approaches outlined in Supplementary Table S1 were applied to the proteins identified in the SSNS and SRNS pre-and post- Table 2 .
Italicized proteins known to be responsive to GCs. Table S2 ).
TRANSLATIONAL RESEARCH
CONCLUSION
NS is a kidney disease that affects both children and adults, and 20% to 50% of patients present with or subsequently develop clinical steroid resistance, which is associated with greatly increased risks for treatment side effects and disease progression. The current study tested the hypothesis that paired plasma proteomic sample analyses could identify candidate biomarkers able to either predict steroid resistance before initial treatment or mechanistically define critical molecular pathways/targets that regulate clinical steroid resistance. We used a pilot proteomic discovery approach in 30 paired plasma samples obtained before and after initial steroid treatment and identified a panel of 13 candidate protein biomarkers predictive of steroid resistance and several candidate biomarkers that mechanistically define specific molecular pathways/ targets of clinical steroid resistance in NS. Candidate biomarkers found to predict steroid resistance included VDB, HPX, Fetuin-B (FETUB), and ADIPOQ (Table 4 ). Candidate protein biomarkers found to mechanistically define specific molecular pathways/targets associated with steroid resistance included VDB, HPX, SHBG, antithrombin-III (SERPINC1), Fetuin-B (FETUB), ADI-POQ, MMP-2, and APOA1. Subsequent confirmatory studies in 74 patient samples of several of these candidate biomarkers by immunoblotting confirmed a few auspicious biomarkers with high potential to be able to either predict steroid resistance or to mechanistically define molecular pathways that regulate steroid resistance in childhood NS (Table 4 ). Proteome profiling of urine, and in some cases serum or plasma, has been analyzed over the past decade in patients with NS using various approaches. 17, [21] [22] [23] [24] [25] [26] More recently, proteomic profiling of patients with NS based on their histology and clinical phenotype has yielded a panel of proteins able to distinguish between these different groups. 16, 17 These studies had important differences from the current study. First, both of these studies analyzed urine samples. Second, neither of these studies included analyses of pretreatment samples that could enable identification of truly predictive biomarkers before initiation of any therapy. Third, the NS classification of Choi et al. 17 was based on histology (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy) and included only adult patients, whereas the classification of Bennett et al. 16 was similarly based on SRNS versus SSNS in children. From the discovery set, a few proteins, such as VDB, antithrombin-III (SERPINC1), and HPX, were common between our predictive markers of SRNS versus SSNS, and the markers of Choi et al., 17 which were able to distinguish among minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy cases. However, none of these markers were validated in the study by Choi et al. 17 In the Bennett et al. 16 study (which had more commonalties in study design), of their 13 identified proteins, VDB, HPX, APOA1, TBG (thyroxine-binding globulin or SERPINA7), a closely related protein to Fetuin-B (Fetuin-A) and zinc-alpha 2 glycoprotein (AZGP1) were commonly identified in our discovery sets of either predictive or mechanistic biomarkers (Tables 2  and 3 ). Of these, VDB, HPX, APOA1, Fetuin-B, and AZGP1 were also identified in our predictive set, of which VDB was validated in both studies. The current study extends these previous findings by combining the use of a state-of-the-art proteomics approach with analyses of paired plasma samples from highly phenotyped children presenting with NS in whom the pretreatment samples were fully verified to represent a "disease-only" state before the administration of even a single dose of steroids. Such careful phenotyping of samples is critical, as we have previously found that even a 30-minute exposure of podocytes to steroids can significantly alter their proteomic profile. 27 Our use of paired samples obtained both pretreatment and posttreatment, when patients had been clinically declared to have either SSNS or SRNS, enabled us to search for potential biomarkers able to both predict subsequent clinical steroid resistance, as well as to search for molecular pathways and targets associated with steroid resistance versus steroid responsiveness.
HPX is a plasma protein with high affinity for heme. A variety of biological activities have been attributed to hemopexin, including both pro-and anti-inflammatory activities. 28 Regarding NS, hemopexin has been shown to induce nephrin-dependent reorganization of the Tables 2 and 3 . A control sample was run on every gel, and test patient samples were normalized to control by densitometry. (c) Western blot semiquantitative comparisons of the candidate biomarker matrix metalloproteinase 2 (MMP-2). MMP-2 immunoblotting of 54 patient samples (16 SSNS and 10 SRNS patients) showed 2 bands, representing the active (lower band, 64 kDa) and proenzyme (upper band, 72 kDa) forms of the enzyme. These were individually semiquantitated by densitometry and the active versus proenzyme ratios measured. Statistical significance was determined by unpaired or paired t tests using the GraphPad Prism software version 6.00 (LaJolla, CA) for Windows. P values were considered significant at P < 0.05 (*P < 0.05 vs. SSNS pretreatment; # P < 0.05 vs. SSNS post-treatment; $ P < 0.05 vs. SRNS pretreatment). ADIPOQ, adiponectin; HPX, hemopexin; SHBG, sex hormone-binding globulin; VDB, vitamin D binding protein.
podocyte actin cytoskeleton, 29 and to distinguish SRNS via a urine proteomics approach, although it was not identified as a candidate on validation by enzymelinked immunosorbent assay (ELISA). 16 Our studies showed that HPX could discriminate patients with SSNS versus SRNS pretreatment, and that steroid treatment significantly increased plasma HPX levels in SSNS (but not SRNS) patients.
APOA1 is an important component of HDL and it has been shown to be present in more heterogeneous forms in the plasma of patients with NS. 30 Dyslipidemia is also a prominent feature of NS, and our study identified APOL1 and other apolipoproteins that could distinguish children with SSNS versus SRNS, both before and after steroid treatment. 7, 8, [31] [32] [33] [34] [35] Adiponectin (ADIPOQ) levels have also been shown to be increased in patients with NS. 36 Our studies found that although adiponectin levels started lower and decreased with steroid treatment in children with SSNS, adiponectin levels started higher and increased further with steroid treatment in those with SRNS.
A few studies have implicated matrix metalloproteinases in the pathogenesis of NS. 37, 38 We found a trend toward higher MMP-2 levels in children with SRNS versus SSNS, both before and following steroid treatment. MMP-2 comprises both an active and a proenzyme form, and our studies underscored a potential role for the relative ratios of these forms, rather than absolute levels, in distinguishing SSNS versus SRNS. 39 Molecular weight forms consistent with higher active/proenzyme ratios in SSNS versus SRNS post-treatment, suggests that increases in this ratio may play a beneficial role in the clinical response to steroids.
Nephrotic rats exhibit urinary loss of SHBG-bound testosterone, and steroid-binding proteins such as SHBG act as gatekeepers of steroid hormone action in the plasma. 40, 41 Our studies showed that SHBG levels increased with steroid treatment in SSNS but decreased in SRNS. These findings may simply reflect reduced urinary losses of SHBG in children with SSNS as they enter remission. However, given the reported role of SHBG in regulating steroid action, these findings may also identify a novel potential opportunity to enhance steroid responsiveness by supplementing or pharmacologically enhancing its production during steroid treatment.
VDB has recently emerged as a urinary marker of steroid resistance in NS, whereas vitamin D has also been reported to have a role in the protection of podocytes against NS-related injury. 16, 42, 43 Our studies in addition identified a 3-protein predictive candidate biomarker panel (VDB, ADIPOQ, and MMP-2) with a significant ability to differentiate at disease presentation patients who will develop SRNS from those who will have SSNS (P ¼ 0.003; area under the receiver operating characteristic curve ¼ 0.78; Table 4 ).
This study had several limitations and strengths. Unlike some previous studies in which ELISA was used for confirmation of identified biomarkers, we used an immunoblotting confirmatory strategy. Although more labor intensive, this strategy enabled significantly improved specificity for the detection of proteins of Approaches defined in Figure 1 . interest. Many antibodies used in ELISAs and immunoblotting bind nonspecifically to other proteins, as we also observed in our blots. Immunoblotting enabled us to successfully circumvent this potential lack of specificity by performing quantitative densitometric analyses of bands, and identify only the proteins of interest. This was specifically relevant for VDB, which belongs to the same gene family and shares significant homology with albumin, and thus could confound confirmatory results using ELISA. 44 This approach also allowed us to evaluate the active versus proenzyme fractions of MMP-2, which is a better marker of its activity than total MMP-2 levels. 45 In addition, immunoblotting enabled the use of small sample volumes compared with ELISAs. To further enhance accuracy, we also used the same control sample in every gel and blot, enabling us to directly normalize all patient samples tested. A larger cohort will be needed in the future to validate the other biomarkers identified in the discovery analysis, as we were not able to validate them all in the present study. Our validation studies were targeted just toward the most relevant/ significant markers known in NS or differentially expressed markers, and were also limited by commercial reagent availability (specific antibodies). The predictive and defining power of the identified proteins is likely to benefit from expanding the validation list in future studies.
Although most similar biomarker studies have been performed using urine, our studies used plasma samples. It would thus be of interest to attempt to further validate our identified biomarkers in urine samples from a larger and separate cohort in the future, and such studies are under way. However, identification of biomarkers in plasma is highly relevant, because it directly reflects the true concentrations of these proteins in blood, without perturbation by renal tubular secretion or reabsorption. Furthermore, SRNS typically presents clinically at older ages with higher average weight than children with SSNS. Because this is a typical generalized difference between the 2 groups, accounting for these confounders was not found to be essential and clinically relevant. Last, we are aware that some of the children with SRNS may have had an underlying genetic cause of disease. However, because these samples were collected over a decade, there were no provisions to screen them for monogenetic causes at that time. Despite this limitation, this study emphasizes differences between children with SRNS and SSNS that are clearly detectable at the time of clinical presentation, regardless of underlying genetic causes, and that would likely be more rapidly available and thus more clinically useful to treating physicians than genetic studies.
A major strength of this study was the evaluation of paired samples from each patient, both before any steroid treatment and following an average of approximately 7 weeks of daily oral steroids. This enabled us to use multiple approaches to analyze the dataset, including identification of potential biomarkers predictive of the subsequent clinical response to steroids, as well as to identify specific mechanistic molecular pathways and/or targets associated with both steroid response and steroid resistance. Because the discovery studies were limited to an all-female subgroup, we expanded our validation cohort to include male and more female patients and using an orthogonal (antibody-based) method, as has been done previously in similar studies. 16 Logistic regression analysis for our candidate predictor biomarker classification of male and female patient samples did not identify sex as a significant classification variable. These logistic regression findings suggest additional studies on the mechanistic candidate biomarkers are justified. Notably, this same group of patient samples has also undergone plasma metabolomics analyses, 46 and future studies will benefit from identification of additional relevant molecular pathways and biomarkers of SRNS using approaches that integrate the proteomics and metabolomics datasets.
In summary, the current studies used paired plasma samples from children with SSNS and SRNS obtained both before and after approximately 7 weeks of daily oral steroids to identify several candidate proteomic biomarkers with the potential to predict subsequent treatment response, and to define specific molecular pathways or targets associated with both steroid sensitivity and steroid resistance. In addition to NS, steroids are also a primary therapy for many other diseases, such as asthma, rheumatoid arthritis, autoimmune hepatitis, and ulcerative colitis. Interestingly, approximately 10% to 30% of these patients also present with or develop steroid resistance during their disease course, leading to increased risks for both drug toxicity and disease progression. Thus, further validation of these results could greatly improve our ability to predict the risk of clinical steroid resistance at disease onset for a large and diverse group of patients. These findings also could improve our understanding of the molecular mechanisms that regulate the clinical response to GCs and help identify potential future molecular targets to improve the treatment of NS as well as other conditions treated with steroids.
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